Tsuda, Hitoshi http://orcid.org/0000-0003-3457-4224
Kurosumi, Masafumi
Akiyama, Futoshi
Ohno, Shinji
Saji, Shigehira
Masuda, Norikazu
Shimomura, Akihiko
Sato, Nobuaki
Takao, Shintaro
Ohsumi, Shozo
Tokuda, Yutaka
Inaji, Hideo
Watanabe, Toru
Funding for this research was provided by:
Taiho Pharmaceutical
Article History
Received: 30 November 2021
Accepted: 13 March 2022
First Online: 18 April 2022
Change Date: 30 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-022-01367-9
Declarations
:
: HT received research grants from Taiho Pharmaceutical and Chugai Pharmaceutical; and personal fees from Roche Diagnostics, Eisai, and AstraZeneca. S Ohno received institute research grants from Eisai and Taiho Pharmaceutical; personal fees from AstraZeneca, Chugai Pharmaceutical, Eisai, Eli Lilly, and Pfizer; and is an executive board member at JBCRG. SS received institute research grants from Taiho Pharmaceutical, Eisai, Chugai Pharmaceutical, Takeda Pharmaceutical, MSD, Novartis, AstraZeneca, Daiichi Sankyo, and Eli Lilly; personal fees from Chugai Pharmaceutical, Kyowa Kirin, MSD, Novartis, Eisai, Takeda Pharmaceutical, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho Pharmaceutical, and Nippon Kayaku; participated on a data safety monitoring board or advisory board of Chugai Pharmaceutical/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and Novartis; and is an executive board member at JBCRG, JBCS, and BIG. NM received institute research grants from Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis, Sanofi, Kyowa Kirin, and Nippon Kayaku; personal fees from Chugai Pharmaceutical, Pfizer, AstraZeneca, Eli Lilly, and Eisai; is an executive board member at JBCRG, and board of directors at JBCS. AS received grants from Chugai Pharmaceutical, Daiichi Sankyo, AstraZeneca, Taiho Pharmaceutical, and Mochida Pharmaceutical; personal fees from Chugai Pharmaceutical, Daiichi Sankyo, AstraZeneca, Novartis, Eli Lilly, Pfizer, Kyowa Kirin, Eisai, Astellas, and MSD. S Ohsumi received lecture fees from AstraZeneca. All other authors declare that they have no conflict of interest.
: The study was approved by the independent ethics committee at each study site. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.